Drug Eluting Balloon Market is Anticipated to Witness High Growth Owing to Rising Prevalence of Cardiovascular Diseases
![]() |
Drug Eluting Balloon Market |
The drug eluting balloon market allows localized drug
delivery at the site of blockages or narrowing in blood vessels. This minimally
invasive procedure helps prevent re-narrowing of arteries post angioplasty by
releasing medication from the inflatable balloon. Drug eluting balloons are
used in procedures like percutaneous coronary intervention and peripheral
artery diseases. With the rising prevalence of atherosclerosis, coronary artery
disease and peripheral artery disease globally, the demand for procedures using
drug eluting balloons is increasing.
The global drug eluting balloon market is estimated to be
valued at US$ 769.29 Bn in 2024 and is expected to exhibit a CAGR of 8.6% over the forecast period
2024 to 2031.
Key Takeaways
Key players operating in the Drug
Eluting Balloon Market Size are Oracle Corporation (NetSuite Inc.),
BatchMaster Software, Columbus Manufacturing, Aquilon Software, CompuTec
S.A.(ProcessForce), Datacor Chempax, DESKERA, ERPAG, Fishbowl, Intellect, SAGE
GROUP plc, and VAI - Vormittag Associates, Inc. These companies are focusing on
new product launches andenhancements to gain a larger market share.
Key opportunities in the market includeemerging economies with large patient
pools and increasing healthcare expenditure. Asia Pacific region is anticipated
to witness highest growth due to growing medical tourism and rising insurance
coverage in countries like India and China.
On the global front, companies are expanding their geographic presence through
strategic collaborations and partnerships. For instance, Medtronic plc
collaborates with local distributors to market its drug coated balloons across
major markets. Boston Scientific also has a strong international presence
across EMEA region and Japan.
Market drivers: The primary driver for this market is the increasing incidence
of cardiovascular diseases worldwide. Some key statistics indicating rising
disease burden are cardiovascular diseases causing over 18 million deaths
annually according to WHO and over 1 in 3 deaths attributable to CVDs in US
according to AHA.
Market restraints: High costs of drug coated devices, lack of reimbursements
and stringent regulatory approvals are some challenges restraining market
growth.Device manufacturing is a highly regulated industry and get-ting
regulatory clearances involves lengthy and expensive clinical trials. This acts
as deterrent for new market entrants.
Segment Analysis
The drug eluting balloon market can be segmented into peripheral and coronary
drug eluting balloon. The peripheral drug eluting balloon segment dominates the
market and accounts for the major share. This is because peripheral diseases
are more common than coronary diseases. Within the peripheral segment, below
the knee arteries sub-segment has highest market share since it is more
difficult to treat diseases in the below knee region.
Global Analysis
The drug eluting balloon market in North America is the fastest growing region
due to rising incidences of cardiovascular diseases and increasing adoption of
minimally invasive surgeries. However, Asia Pacific dominates the global market
and is expected to grow at highest CAGR during the forecast period. This is
because of rising health awareness, increasing healthcare expenditure, and
growth of medical tourism in the countries of Asia Pacific such as China,
India, and Japan.
Explore Our More Blogs on Drug
Eluting Balloon Market
Comments
Post a Comment